{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:42:34Z","timestamp":1787859754606,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024250","name":"Israel Innovation Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.neurot.2024.e00335","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T11:03:20Z","timestamp":1708081400000},"page":"e00335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6\/2 mouse model"],"prefix":"10.1016","volume":"21","author":[{"given":"Talya","family":"Shacham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Offen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo Z.","family":"Lederkremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00335_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015245","article-title":"Formation and toxicity of soluble polyglutamine oligomers in living cells","volume":"5","author":"Lajoie","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00335_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"21","key":"10.1016\/j.neurot.2024.e00335_bib3","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1093\/hmg\/ddm217","article-title":"Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity","volume":"16","author":"Atwal","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"23","key":"10.1016\/j.neurot.2024.e00335_bib4","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1101\/gad.1673408","article-title":"Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity","volume":"22","author":"Duennwald","year":"2008","journal-title":"Genes Dev"},{"issue":"Pt 19","key":"10.1016\/j.neurot.2024.e00335_bib5","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1242\/jcs.087510","article-title":"Changes in BiP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin","volume":"124","author":"Lajoie","year":"2011","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.neurot.2024.e00335_bib6","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/ncomms3753","article-title":"Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress","volume":"4","author":"Leitman","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00335_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fmolb.2019.00020","article-title":"Protein misfolding and ER stress in huntington's disease","volume":"6","author":"Shacham","year":"2019","journal-title":"Front Mol Biosci"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00335_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090803","article-title":"ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin","volume":"9","author":"Leitman","year":"2014","journal-title":"PLoS One"},{"issue":"6716","key":"10.1016\/j.neurot.2024.e00335_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/16729","article-title":"Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase","volume":"397","author":"Harding","year":"1999","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00335_bib10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.cell.2021.02.007","article-title":"Adapting the proteostasis capacity to sustain brain healthspan","volume":"184","author":"Hetz","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00335_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/biom11030354","article-title":"PERK pathway and neurodegenerative disease: to inhibit or to activate?","volume":"11","author":"Shacham","year":"2021","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00335_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1747-0285.2010.01048.x","article-title":"Structural determinants of PERK inhibitor potency and selectivity","volume":"76","author":"Wang","year":"2010","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00335_bib13","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1038\/s41598-020-63899-4","article-title":"A\u00a0novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models","volume":"10","author":"Ganz","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00335_bib14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1152\/jn.00762.2011","article-title":"A\u00a0critical window of CAG repeat-length correlates with phenotype severity in the R6\/2 mouse model of Huntington's disease","volume":"107","author":"Cummings","year":"2011","journal-title":"J\u00a0Neurophysiol"},{"key":"10.1016\/j.neurot.2024.e00335_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuropharm.2017.07.029","article-title":"Grip strength in mice with joint inflammation: a rheumatology function test sensitive to pain and analgesia","volume":"125","author":"Montilla-Garc\u00eda","year":"2017","journal-title":"Neuropharmacology"},{"issue":"Pt 5","key":"10.1016\/j.neurot.2024.e00335_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1107\/S0907444911006445","article-title":"The structure of the PERK kinase domain suggests the mechanism for its activation","volume":"67","author":"Cui","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00335_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.15252\/emmm.201606664","article-title":"PERK activation mitigates tau pathology in vitro and in vivo","volume":"9","author":"Bruch","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00335_bib18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1212\/01.WNL.0000031791.10922.CF","article-title":"Weight loss in early stage of Huntington's disease","volume":"59","author":"Djouss\u00e9","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00335_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/hmg\/ddi053","article-title":"The R6\/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient \u03b2-cell mass and exocytosis","volume":"14","author":"Bj\u00f6rkqvist","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00335_bib20","article-title":"Evaluating gait and locomotion in rodents with the CatWalk","volume":"1","author":"Garrick","year":"2021","journal-title":"Curr Protoc"},{"key":"10.1016\/j.neurot.2024.e00335_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2202-11-92","article-title":"Automated quantitative gait analysis in animal models of movement disorders","volume":"11","author":"Vandeputte","year":"2010","journal-title":"BMC Neurosci"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00335_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","article-title":"Mouse models of Huntington's disease and methodological considerations for therapeutic trials","volume":"1792","author":"Ferrante","year":"2009","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.neurot.2024.e00335_bib23","article-title":"Current and possible future therapeutic options for Huntington's disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J\u00a0Cent Nerv Syst Dis"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00335_bib24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.neuron.2019.05.001","article-title":"Huntingtin lowering strategies for disease modification in huntington's disease","volume":"102","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00335_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"10.1016\/j.neurot.2024.e00335_bib26","first-page":"3951","article-title":"Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress","volume":"27","author":"Yuan","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"46","key":"10.1016\/j.neurot.2024.e00335_bib27","doi-asserted-by":"crossref","first-page":"15692","DOI":"10.1074\/jbc.REV120.010218","article-title":"Small molecule strategies to harness the unfolded protein response: where do we go from here?","volume":"295","author":"Grandjean","year":"2020","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00335_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020780","article-title":"Impact of ER stress and ER-mitochondrial crosstalk in huntington's disease","volume":"23","author":"Maity","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00335_bib29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41593-022-01185-4","article-title":"Age-related Huntington's disease progression modeled in directly reprogrammed patient-derived striatal neurons highlights impaired autophagy","volume":"25","author":"Oh","year":"2022","journal-title":"Nat Neurosci"},{"issue":"5711","key":"10.1016\/j.neurot.2024.e00335_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1126\/science.1101902","article-title":"A\u00a0selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress","volume":"307","author":"Boyce","year":"2005","journal-title":"Science (New York, N.Y.)"},{"issue":"6231","key":"10.1016\/j.neurot.2024.e00335_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.aaa4484","article-title":"Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit","volume":"348","author":"Das","year":"2015","journal-title":"Science (New York, N.Y.)"},{"issue":"6025","key":"10.1016\/j.neurot.2024.e00335_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.1201396","article-title":"Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis","volume":"332","author":"Tsaytler","year":"2011","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.neurot.2024.e00335_bib33","article-title":"Prevention of huntington's disease-like behavioral deficits in R6\/1 mouse by tolfenamic acid is associated with decreases in mutant huntingtin and oxidative stress","volume":"2019","author":"Liu","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00335_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21900-2","article-title":"Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease","volume":"12","author":"Galyan","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00335_bib35","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1038\/s41598-017-04990-1","article-title":"Laquinimod treatment in the R6\/2 mouse model","volume":"7","author":"Ellrichmann","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00335_bib36","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s12035-019-01847-8","article-title":"Neuroprotective effects of doxycycline in the R6\/2 mouse model of huntington's disease","volume":"57","author":"Paldino","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00335_bib37","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.neurot.2024.e00335_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136180","article-title":"Rescue of BDNF expression by the thalamic\u00a0parafascicular nucleus with chronic treatment with the mGluR2\/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6\/2 Huntington's disease mice","volume":"763","author":"Wang","year":"2021","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00335_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41467-022-35752-x","article-title":"Transcriptional vulnerabilities of striatal neurons in human and rodent models of Huntington's disease","volume":"14","author":"Matsushima","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00335_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.1022251","article-title":"Distinct histological alterations of cortical interneuron types in mouse models of Huntington's disease","volume":"16","author":"Voelkl","year":"2022","journal-title":"Front Neurosci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:13:38Z","timestamp":1761808418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1878747924000217"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00335","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2594607\/v1","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6\/2 mouse model","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00335"}}